New results of the ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation) trial have been presented today at the European Society of Hypertension (ESH) and show that the antihypertensive Preterax - a fixed combination of the ACE-inhibitor perindopril and the diuretic indapamide - reduces the likelihood of new or worsening nephropathy (kidney damage) in patients with type 2 diabetes mellitus by up to 31% and in patients with existing kidney damage leads to nephropathy regression in about one-in-six.(1)

In this new ADVANCE analysis, Preterax reduces the risk of developing new onset microalbuminuria by 21% (P Blood pressure strongly influences the risk of developing microalbuminuria and its progression to nephropathy.(6) In patients with hypertension, nephropathy strongly predicts the risk of future cardiovascular events and death.(2) Patients with end stage kidney disease need dialysis or a kidney transplant.


ADVANCE involved 11,140 type 2 diabetic patients from more than 20 countries followed up, on average, for 4.3 years. It is a multicentre, randomised, placebo-controlled study that enrolled both patients with normal blood pressure (normotensive) and hypertensives from 20 countries. Patients already received usual treatments for type 2 diabetes, including other antihypertensives.

In ADVANCE, the average blood pressure fell below 135/75 mmHg in patients treated with Preterax, possibly the best BP control yet achieved in a major trial in type 2 diabetes. Previous results from ADVANCE showed that Preterax reduces total mortality by 14% and cardiovascular death by 18% in type 2 diabetes patients. Therefore, Preterax would avoid one death for every 79 patients treated for five years. In addition, Preterax reduced total coronary events by 14%. Preterax would avoid one coronary event for every 75 patients treated for five years. Global benefits of Preterax in the renal function were already demonstrated in the main analysis of ADVANCE, with a reduction of the risk of all renal events by 21% compared with placebo (P

Tag Cloud